Clinical study

Automated, consistent scoring of the UCEIS could reduce subjectivity and variability in endoscopic assessment of ulcerative colitis, which matters for clinical trials, central reading, and potentially treatment decisions...

Steroid dependency affects many people with ulcerative colitis and can change long-term treatment plans. This study explores clinical factors and uses an AI clustering method to visualize different risk patterns, which...

The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...

Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.

ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....

Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...

The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.

The analysis suggests genetic liability to IBD, particularly Crohn’s disease, may raise the risk of IgA vasculitis. This is relevant for understanding overlapping immune mechanisms and possible shared pathways between...

Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...

This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...

Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.

This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...

Metabolic syndrome appears common in this Tunisian IBD cohort (about one-third). MetS can affect overall health and may influence long-term outcomes for people with IBD, so awareness and cardiometabolic screening may be...

Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...

If you have IBD and joint symptoms, this study suggests your joint complaints may reflect measurable immune changes that partly overlap with spondyloarthritis, not just non-specific pain. That could mean joint symptoms...

Fatigue is a common, disabling symptom in people with IBD with unclear causes. Finding reproducible immune or infectious signatures related to fatigue could point toward new research directions and, eventually, markers...

Sarcopenia is common in Crohn's disease and is linked to worse outcomes; a simple GNRI-based prediction tool could help identify at-risk patients without routine CT scanning.

Finding monogenic causes in infants with congenital diarrheas or VEOIBD can directly affect diagnosis, genetic counseling, and management. Populations with higher consanguinity may have higher diagnostic yields for...

Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...

Identifying genetic predictors of thiopurine-induced leukopenia could help prevent a serious drug side effect by improving pre-treatment genetic screening and dose decisions for people with IBD.

This study looks at how statistically "fragile" results are in trials of new IBD treatments. Patients and clinicians should know that trial size, treatment type, and whether the result was a primary outcome affect how...

The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...

If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...

Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...

This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...

Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.

If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.

The 1955 Truelove and Witts criteria do not account for patients already on modern outpatient therapies. Updated consensus criteria could change how ASUC is recognized and triaged in current clinical practice.

If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...

Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...

Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...

This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...

An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.

This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

The work suggests a fungus-derived metabolite can reduce experimental colitis through AhR and NF-κB pathways, highlighting a potential new direction for microbiome‑based therapies or postbiotics that could eventually...

The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.

The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...

The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...

Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be...

Automated, sequence-robust MRI measures could help standardize detection and localization of perianal anoperineal lesions in Crohn’s disease, which is relevant for diagnosis and management of perianal complications.

A majority of surveyed IBD patients who use marijuana reported better quality of life and relief from symptoms such as nausea, joint pain, insomnia and anxiety — findings of interest to people seeking symptom management...

The study suggests Artemisia rupestris extract can reduce inflammation, repair the intestinal barrier, and shift the gut microbiota and metabolites in a mouse colitis model — pathways that are important in IBD. These...

The study investigates how components of exclusive enteral nutrition (EEN), particularly transforming growth factor‑β (TGF‑β), may help restore intestinal barrier function after colitis. That could help explain why EEN...

This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...

The paper suggests that loss of microbial bile acid transformations in IBD reduces activation of the TGR5 receptor, and that lower TGR5 bioactivity correlates with higher inflammatory activity — a potential mechanism...